May 24, 2022

The Honorable Robert Scott Chair, Education & Labor Committee U.S. House of Representatives

The Honorable Virginia Foxx Ranking Member, Education & Labor Committee, U.S. House of Representatives The Honorable Patty Murray Chair, Senate Committee on Health, Education, Labor, & Pensions, U.S. Senate

The Honorable Richard Burr Ranking Member, Senate Committee on Health, Education, Labor & Pensions, U.S. Senate

Dear Chair Scott, Ranking Member Foxx, Chair Murray, Ranking Member Burr, and Members of the House Education & Labor Committee and Senate Health, Education, Labor, & Pensions Committee:

On behalf of the 75 undersigned patient and provider advocacy groups, we urge you to support timely access to needed medical treatments as part of your plans for a mental health package and to address provider burnout. Specifically, we ask that such legislation include step therapy reform in ERISA health plans, as outlined in the Safe Step Act (HR 2163/S 464).

Step therapy is a protocol used by health insurers that requires patients to try and fail one or more insurer-preferred medications before the insurer will cover the medication initially prescribed and agreed upon by the patient and their provider. Step therapy is widely used by health plans – a recent study on commercial plans found that almost 40% of prescriptions were subject to step therapy and that protocols varied greatly from plan to plan, even for the same condition.¹ Because it can take 2-3 months for patients to prove failure, medically inappropriate step therapy delays access to needed care and can result in devastating health outcomes for the patient.

As with other chronic illnesses, medication is an important treatment option for people with mental illnesses as well as those suffering from substance use disorder (SUD).^{2 3} However, insurance-mandated step therapy can reduce medication adherence, increase serious adverse events, and increase costs:

 A study on anti-depressant medication coverage in employer plans found that step therapy reduced medication adherence and, within a quarter following the implementation of step therapy, increased mental health-related outpatient, inpatient, and emergency room visits by nearly 20%.⁴ The authors noted that "emergency room spending in the step therapy plans consistently exceeded the spending levels of the comparison group."

¹ Variation In Use and Content of Prescription Drug Step Therapy Protocols, Within and Across Health Plans. Kelly L. Lenahan, Donald E. Nichols, Rebecca M. Gertler, and James D. Chambers. Health Affairs 2021 40:11, 1749-1757 ² Medications: Step Therapy. National Alliance on Mental Illness, <u>https://www.nami.org/Advocacy/Policy-Priorities/Improving-Health/Medications-Step-Therapy</u>

³ NIDA. "Treatment Approaches for Drug Addiction DrugFacts." National Institute on Drug Abuse, 17 Jan. 2019, <u>https://nida.nih.gov/publications/drugfacts/treatment-approaches-drug-addiction</u> Accessed 29 Apr. 2022.

⁴ The Effects of Antidepressant Step Therapy Protocols on Pharmaceutical and Medical Utilization and Expenditures. Tami L. Mark, Teresa M. Gibson, Kimberly McGuigan, and Bong Chul Chu, American Journal of Psychiatry 2010 167:10, 1202-1209

- A study among Medicaid patients found that the impact of delays in needed care among patients with a mental illness and/or substance use disorder (SUD) included an emergency visit, psychiatric hospitalization, increase in suicidal or violent ideation or behavior, homelessness, or incarceration in prison or detention in jail.⁵ This study also found that step therapy was associated with a 4.7 times greater likelihood of a mental health medication access problem.
- Alcohol and drug use is a leading cause of death in the U.S., and health plans spend 1% or less of their health expenditures on treatment – in part because of utilization management like step therapy which discourage patients from pursuing access to needed care.⁶

In addition, patients with other illnesses are more likely to have comorbid mental illness. Comorbid mental illness is also associated with greater healthcare utilization and costs. It is important to ensure that *all patients* have timely access to needed care to limit disease progression, reduce utilization, and reduce costs.

- Among Alberta chronic illness patients, co-occurring mental illness was associated with higher healthcare utilization and costs.⁷
- About 1 in 5 US adults with arthritis have symptoms of anxiety or depression, especially among those living with chronic pain or other co-occurring chronic conditions according to the CDC. "Not only are symptoms of anxiety and depression common among US adults with chronic conditions, but these symptoms also have also been associated with reduced response to treatment and poorer quality of life."⁸
- Among patients with inflammatory bowel disease, depression was associated with more aggressive disease,⁹ and comorbid mental illness associated with higher surgical costs.¹⁰
- The prevalence of depression in patients with psoriasis may be higher than 50%. Studies have shown that psoriasis patients experience physical and mental disability just like patients with other chronic illnesses such as cancer, arthritis, hypertension, heart disease, and diabetes.^{11 12}

⁶ American Society for Addiction Medicine. Third Party Payment for Addiction Treatment. <u>https://www.asam.org/advocacy/public-policy-statements/details/public-policy-statements/2020/04/22/third-party-payment-for-addiction-treatment</u>

doi:10.1001/jamanetworkopen.2019.9910

⁵ Medicaid Prescription Drug Policies and Medication Access and Continuity: Findings from Ten States Joyce C. West, Ph.D., M.P.P., et al. Psychiatric Services 2009 60:5, 601-610

⁷ Sporinova, Barbora et al. "Association of Mental Health Disorders with Health Care Utilization and Costs Among Adults with Chronic Disease." JAMA network open vol. 2,8 e199910. 2 Aug. 2019,

⁸ CDC: The Arthritis-Mental Health Connection. October 2021.

https://www.cdc.gov/arthritis/communications/features/arthritis-mental-health.htm

⁹ Kochar, Bharati et al. "Depression Is Associated with More Aggressive Inflammatory Bowel Disease." The American journal of gastroenterology vol. 113,1 (2018): 80-85. doi:10.1038/ajg.2017.423

¹⁰ Szigethy, Eva et al. "Mental Health Costs of Inflammatory Bowel Diseases." Inflammatory bowel diseases vol. 27,1 (2021): 40-48. doi:10.1093/ibd/izaa030

¹¹ Dowlatshahi, E. A., Wakkee., Arends, L. R., & Nijsten, T. (2014). The prevalence and odds of depressive symptoms and clinical depression in psoriasis patients: a systematic review and meta-analysis. Journal of Investigative Dermatology, 134(6), 1542-1551

¹² Mentor A, Korman NJ, Elmets CA, Feldman SR, Gelfand JM, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 3. Guidelines of care for the treatment of psoriasis with topical therapies. J Am Acad Dermatol 2009 April; 60(4): 643-659

Given the abysmal health outcomes among patients subject to medically inappropriate step therapy, unsurprisingly utilization management exacerbates provider burnout which is already a national problem due to the COVID-19 pandemic. According to the American Medical Association, 88% of physicians describe the burden of prior authorization (PA) high or extremely high, 40% report having dedicated staff to manage PAs, and physicians report spending two business days per week on PAs.¹³ The American College of Gastroenterology (ACG) recently reported that PA is "harming patients and overwhelming practices."¹⁴

The Safe Step Act (HR 2163/S 464) would improve patient outcomes, reduce costs, and improve provider experience by ensuring that employer plans offer a medically reasonable and expedient step therapy exceptions process. This bill, first introduced in 2017, is modeled after legislation that has passed in over 30 states. These state laws apply to state-regulated plans including the individual marketplace, and such patient protections must be extended to federally regulated ERISA health plans.

As patient and provider advocacy organizations representing millions of beneficiaries and their health care providers, we urge you to include step therapy reform in legislation that addresses mental health and/or provider burnout. If you would like to discuss this important policy further, or if you have any questions, please contact Alisa Vidulich, Policy Director at the Arthritis Foundation, at <u>avidulich@arthritis.org</u>. Thank you for your consideration of this critical patient access concern.

Sincerely,

ADAP Advocacy Association Aimed Alliance Allergy & Asthma Network Alliance for Patient Access American Academy of Dermatology Association American Academy of Neurology American Academy of Ophthalmology American College of Rheumatology American Gastroenterological Association American Partnership for Eosinophilic Disorders American Society for Gastrointestinal Endoscopy American Society for Parenteral and Enteral Nutrition Arizona Peer and Family Coalition Arizona Prostate Cancer Coalition, Inc. Arizona Psychiatric Society Arthritis Foundation Association of Black Cardiologists **Caregiver Action Network Child Neurology Foundation Chronic Disease Coalition Coalition of Skin Diseases**

¹³ 2021 AMA prior authorization (PA) physician survey. <u>https://www.ama-assn.org/system/files/prior-authorization-survey.pdf</u>

¹⁴ ACG. Prior Authorization: Harming Patients and Overwhelming Practices. <u>https://webfiles.gi.org/links/policy/PriorAuthorizationHarmingPatientsandOverwhelmingPractices.pdf</u>

Coalition of State Rheumatology Organizations Community Access National Network (CANN) Connecting to Cure Crohn's and Colitis Crohn's & Colitis Foundation CURED Nfp (Campaign Urging Research for Eosinophilic Disease) **Depression and Bipolar Support Alliance Digestive Disease National Coalition Epilepsy Alliance America Epilepsy Foundation** Fabry Support & Information Group **Georgia AIDS Coalition** Gilda's Club South Florida Hawai'i Parkinson Association HD Reach HealthyWomen **Hope Charities** ICAN, International Cancer Advocacy Network International Foundation for AiArthritis International Foundation for Gastrointestinal Disorders (IFFGD) **International Pain Foundation** Louisiana Hemophilia Foundation Lupus and Allied Diseases Association, Inc. Lupus Foundation of America **Movement Disorders Policy Coalition** Multiple Sclerosis Association of America **Multiple Sclerosis Foundation** National Alliance of State Prostate Cancer Coalitions National Council for Mental Wellbeing National Eczema Association National MS Society National Organization for Rare Disorders National Organization for Tardive Dyskinesia National Pancreas Foundation National Patient Advocate Foundation National Psoriasis Foundation National Psoriasis Foundation Nebraska Pharmacists Association Nevada Chronic Care Collaborative North American Society for Pediatric Gastroenterology, Hepatology and Nutrition Parkinson's Foundation PlusInc Society of Dermatology Physician Assistants Spondylitis Association of America State of Texas Association of Rheumatologists Susan G. Komen The Arc of Nebraska The Leukemia & Lymphoma Society The Michael J. Fox Foundation for Parkinson's Research

Transplant Recipients International Organization (TRIO) TSC Alliance U.S. Pain Foundation United Ostomy Associations of America VHL Alliance ZERO - The End of Prostate Cancer

CC: Speaker Nancy Pelosi Majority Leader Charles Schumer Minority Leader Mitch McConnell Minority Leader Kevin McCarthy House Committee on Education and Labor Members House Committee on Energy & Commerce Chairman Frank Pallone, Jr. House Committee on Energy & Commerce Ranking Member Cathy McMorris Rodgers House Committee on Energy & Commerce Chairwoman, Health Subcommittee Anna Eshoo House Committee on Energy & Commerce Ranking Member, Health Subcommittee Brett Guthrie House Committee on Energy & Commerce Committee Members Senate Committee on Health, Education, Labor, and Pensions Members